{"id":30940,"date":"2024-10-08T10:39:27","date_gmt":"2024-10-08T08:39:27","guid":{"rendered":"https:\/\/sma.selfempowered.net\/smanews\/?p=29490"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"sapphire-studie-erreicht-primaeren-endpunkt-zulassung-geplant","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/sapphire-studie-erreicht-primaeren-endpunkt-zulassung-geplant\/","title":{"rendered":"SAPPHIRE Studie erreicht prim\u00e4ren Endpunkt &#8211; Zulassung geplant."},"content":{"rendered":"\n<p>Scholar Rocks <a href=\"https:\/\/sma.selfempowered.net\/smafaqs\/was-ist-apitegromab\/\">Apitegromab<\/a> ist wohl vermutlich auf einem guten Weg auch bald verf\u00fcgbar zu werden &#8230;. wobei &#8220;bald&#8221; hier nat\u00fcrlich schon doch auch noch 1&#8211;2 Jahre bedeuten kann! Zulassung von Medikamenten ist eben immer ein langer Prozess.<\/p>\n\n\n\n<p>Aber wie in letztem Medi-Release vom 07.10.2024 zu lesen ist, erreichte die <a href=\"https:\/\/sma.selfempowered.net\/smafaqs\/was-ist-die-sapphire-studie\/\" data-type=\"link\" data-id=\"https:\/\/sma.selfempowered.net\/smafaqs\/was-ist-die-sapphire-studie\/\">SAPPHIRE<\/a> Studie nun ihren prim\u00e4ren Endpunkt, mit guten Ergebnissen. Scholar Rock plant nun, die Zulassung f\u00fcr den europ\u00e4ischen Raum im ersten Quartal 2025 einzureichen.<\/p>\n\n\n\n<p>Quelle: <a href=\"https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-reports-apitegromab-meets-primary-endpoint-phase-3\">https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/scholar-rock-reports-apitegromab-meets-primary-endpoint-phase-3<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Scholar Rocks Apitegromab ist wohl vermutlich auf einem guten Weg auch bald verf\u00fcgbar zu werden &#8230;. wobei &#8220;bald&#8221; hier nat\u00fcrlich schon doch auch noch 1&#8211;2 Jahre bedeuten kann! Zulassung von Medikamenten ist eben immer ein langer Prozess. Aber wie in letztem Medi-Release vom 07.10.2024 zu lesen ist, erreichte die SAPPHIRE Studie nun ihren prim\u00e4ren Endpunkt, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-30940","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/30940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=30940"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/30940\/revisions"}],"predecessor-version":[{"id":39760,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/30940\/revisions\/39760"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=30940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=30940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=30940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}